Internal Medicine, Endocrinology, Diabetes, & Metabolism · Houston, TX
NPI
1497962252
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1515 Holcombe Blvd
Houston, TX, 77030
Phone (713) 792-6161
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
319 services
Medicare patients, 2024
199
Average age 71
Drug cost, 2024
$2.2M
270 prescriptions
Company payments, 2024
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mimi I Hu was code 99215 (office e&m - established), 83 times for 61 patients. In total Mimi I Hu billed 319 services in 13 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-07-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 83 | 61 | $96.87 | $8,040 |
| 99214 Office E&M - Established | Facility | 81 | 78 | $67.39 | $5,459 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 31 | 25 | $12.82 | $397 |
| 99205 Office E&M - New | Facility | 23 | 23 | $133.75 | $3,076 |
| 99215 Office E&M - Established | Office | 20 | 18 | $121.32 | $2,426 |
| 99213 Office E&M - Established | Facility | 16 | 16 | $45.91 | $734 |
By year: 2022 $27K for 340 services; 2023 $28K for 335 services; 2024 $24K for 319 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mimi I Hu prescribed most often to Medicare patients was Levothyroxine Sodium, with 37 prescriptions and refills. In total Mimi I Hu wrote 270 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 37 | 95 | 17 | $656 |
| Gavreto Pralsetinib | 29 | 33 | Under 11 | $507K |
| Tafinlar Dabrafenib Mesylate | 29 | 29 | Under 11 | $405K |
| Mekinist Trametinib Dimethyl Sulfoxide | 28 | 28 | Under 11 | $422K |
| Synthroid Levothyroxine Sodium | 26 | 44 | Under 11 | $1,769 |
| Caprelsa Vandetanib | 18 | 18 | Under 11 | $214K |
| Levoxyl Levothyroxine Sodium | 15 | 15 | Under 11 | $155 |
| Everolimus Generic | 14 | 14 | Under 11 | $104K |
| Lenvima Lenvatinib Mesylate | 12 | 12 | Under 11 | $289K |
Brand drugs: 189 claims; generic drugs: 81 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Mimi I Hu $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.